175 related articles for article (PubMed ID: 37976135)
21. A Caenorhabditis elegans model of adenylosuccinate lyase deficiency reveals neuromuscular and reproductive phenotypes of distinct etiology.
Fenton AR; Janowitz HN; Franklin LP; Young RG; Moro CA; DeGennaro MV; McReynolds MR; Wang W; Hanna-Rose W
Mol Genet Metab; 2023 Nov; 140(3):107686. PubMed ID: 37607437
[TBL] [Abstract][Full Text] [Related]
22. Effect of dacarbazine on CD44 in live melanoma cells as measured by atomic force microscopy-based nanoscopy.
Huang X; He J; Zhang HT; Sun K; Yang J; Wang H; Zhang H; Guo Z; Zha ZG; Zhou C
Int J Nanomedicine; 2017; 12():8867-8886. PubMed ID: 29296081
[TBL] [Abstract][Full Text] [Related]
23. Post hoc economic analysis of temozolomide versus dacarbazine in the treatment of advanced metastatic melanoma.
Hillner BE; Agarwala S; Middleton MR
J Clin Oncol; 2000 Apr; 18(7):1474-80. PubMed ID: 10735895
[TBL] [Abstract][Full Text] [Related]
24. Bacillus Calmette-Guérin immunotherapy in combination with DTIC (NSC-45388) for the treatment of malignant melanoma.
Gutterman JU; Mavligit GM; Reed R; Burgess MA; Gottlieb J; Hersh EM
Cancer Treat Rep; 1976 Feb; 60(2):177-82. PubMed ID: 769970
[TBL] [Abstract][Full Text] [Related]
25. In vitro activation of dacarbazine (DTIC) for a human tumor cloning system.
Metelmann HR; Von Hoff DD
Int J Cell Cloning; 1983 Apr; 1(1):24-32. PubMed ID: 6674387
[TBL] [Abstract][Full Text] [Related]
26. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.
Avril MF; Aamdal S; Grob JJ; Hauschild A; Mohr P; Bonerandi JJ; Weichenthal M; Neuber K; Bieber T; Gilde K; Guillem Porta V; Fra J; Bonneterre J; Saïag P; Kamanabrou D; Pehamberger H; Sufliarsky J; Gonzalez Larriba JL; Scherrer A; Menu Y
J Clin Oncol; 2004 Mar; 22(6):1118-25. PubMed ID: 15020614
[TBL] [Abstract][Full Text] [Related]
27. Ipilimumab for Previously Untreated Unresectable Malignant Melanoma: A Critique of the Evidence.
Giannopoulou C; Sideris E; Wade R; Moe-Byrne T; Eastwood A; McKenna C
Pharmacoeconomics; 2015 Dec; 33(12):1269-79. PubMed ID: 26043718
[TBL] [Abstract][Full Text] [Related]
28. Effect of dacarbazine (DTIC) on cultures from malignant melanoma of the choroid: an immunohistochemical and electron microscopic study.
Sivkova N; Steuhl KP; Rohrbach J; Popova L
Folia Med (Plovdiv); 1999; 41(3):5-11. PubMed ID: 10658360
[TBL] [Abstract][Full Text] [Related]
29. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma.
Middleton MR; Grob JJ; Aaronson N; Fierlbeck G; Tilgen W; Seiter S; Gore M; Aamdal S; Cebon J; Coates A; Dreno B; Henz M; Schadendorf D; Kapp A; Weiss J; Fraass U; Statkevich P; Muller M; Thatcher N
J Clin Oncol; 2000 Jan; 18(1):158-66. PubMed ID: 10623706
[TBL] [Abstract][Full Text] [Related]
30. Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma.
Maio M; Mackiewicz A; Testori A; Trefzer U; Ferraresi V; Jassem J; Garbe C; Lesimple T; Guillot B; Gascon P; Gilde K; Camerini R; Cognetti F;
J Clin Oncol; 2010 Apr; 28(10):1780-7. PubMed ID: 20194853
[TBL] [Abstract][Full Text] [Related]
31. Molecular characterization of the AdeI mutant of Chinese hamster ovary cells: a cellular model of adenylosuccinate lyase deficiency.
Vliet LK; Wilkinson TG; Duval N; Vacano G; Graham C; Zikánová M; Skopova V; Baresova V; Hnízda A; Kmoch S; Patterson D
Mol Genet Metab; 2011 Jan; 102(1):61-8. PubMed ID: 20884265
[TBL] [Abstract][Full Text] [Related]
32. Health-related quality of life in patients with advanced metastatic melanoma: results of a randomized phase III study comparing temozolomide with dacarbazine.
Kiebert GM; Jonas DL; Middleton MR
Cancer Invest; 2003; 21(6):821-9. PubMed ID: 14735685
[TBL] [Abstract][Full Text] [Related]
33. Dacarbazine inhibits proliferation of melanoma FEMX-1 cells by up-regulating expression of miRNA-200.
Chen YN
Eur Rev Med Pharmacol Sci; 2017 Mar; 21(6):1191-1197. PubMed ID: 28387914
[TBL] [Abstract][Full Text] [Related]
34. Tyrosinase overexpression promotes ATM-dependent p53 phosphorylation by quercetin and sensitizes melanoma cells to dacarbazine.
Thangasamy T; Sittadjody S; Limesand KH; Burd R
Cell Oncol; 2008; 30(5):371-87. PubMed ID: 18791269
[TBL] [Abstract][Full Text] [Related]
35. Combined Therapy with Dacarbazine and Hyperthermia Induces Cytotoxicity in A375 and MNT-1 Melanoma Cells.
Salvador D; Bastos V; Oliveira H
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408947
[TBL] [Abstract][Full Text] [Related]
36. Topical CpG enhances the response of murine malignant melanoma to dacarbazine.
Najar HM; Dutz JP
J Invest Dermatol; 2008 Sep; 128(9):2204-10. PubMed ID: 18368132
[TBL] [Abstract][Full Text] [Related]
37. Structural and biochemical characterization of human adenylosuccinate lyase (ADSL) and the R303C ADSL deficiency-associated mutation.
Ray SP; Deaton MK; Capodagli GC; Calkins LA; Sawle L; Ghosh K; Patterson D; Pegan SD
Biochemistry; 2012 Aug; 51(33):6701-13. PubMed ID: 22812634
[TBL] [Abstract][Full Text] [Related]
38. Influence of therapy on the antioxidant status in patients with melanoma.
Gadjeva V; Dimov A; Georgieva N
J Clin Pharm Ther; 2008 Apr; 33(2):179-85. PubMed ID: 18315784
[TBL] [Abstract][Full Text] [Related]
39. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview.
Serrone L; Zeuli M; Sega FM; Cognetti F
J Exp Clin Cancer Res; 2000 Mar; 19(1):21-34. PubMed ID: 10840932
[TBL] [Abstract][Full Text] [Related]
40. LncRNA POU3F3 Contributes to Dacarbazine Resistance of Human Melanoma Through the MiR-650/MGMT Axis.
Wu K; Wang Q; Liu YL; Xiang Z; Wang QQ; Yin L; Liu SL
Front Oncol; 2021; 11():643613. PubMed ID: 33816296
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
